High Tide completed the acquisition of a 51% stake in Remexian Pharma for €26.4m.

High Tide, a vertically integrated cannabis company, completed the acquisition of a 51% stake in Remexian Pharma, a German medical cannabis distributor, for €26.4m. "Today marks a transformational moment in High Tide's journey as we officially plant our flag in Europe. With the closing of this majority acquisition of Remexian, High Tide is no longer just a Canadian success story—we are now a global cannabis company with real scale in Europe's largest federally regulated market," Raj Grover, High Tide Founder and Chief Executive Officer.